Medicine overview
Indications of Renosev
Renosev is a non-calcium, non-absorbed phosphate-binding agent indicated for the control of serum phosphorus (hyperphosphatemia) in patients with chronic kidney disease (CKD).
- Established/labeled use: Control of serum phosphorus in adults and pediatric patients 6 years of age and older with CKD who are on dialysis (haemodialysis or peritoneal dialysis).
- Guideline-supported/regional use: In some markets, Renosev is also indicated for control of serum phosphorus in adults with CKD not yet on dialysis, when serum phosphorus is significantly elevated, generally alongside dietary phosphate restriction.
- Adjunct role: Renosev is typically used together with calcium supplementation and active vitamin D (or its analogues) as part of a comprehensive plan to manage CKD-mineral and bone disorder; it does not treat the underlying kidney disease itself.
Renosev is not approved for patients without hyperphosphatemia or with normal renal function.
Composition
Description
Renosev is a synthetic, non-calcium, non-absorbed polymeric compound that binds dietary phosphate in the gastrointestinal tract, reducing the amount of phosphorus available for absorption into the bloodstream.
It is used as a phosphate-lowering agent in patients whose kidneys can no longer adequately excrete phosphorus, most commonly in advanced chronic kidney disease requiring dialysis. Renosev is supplied as film-coated tablets and, in some markets, as a powder for oral suspension.
Therapeutic Class
Renosev belongs to the therapeutic class of phosphate-binding agents (non-calcium-based phosphate binders), used in the management of hyperphosphatemia associated with chronic kidney disease.
Pharmacology
Sevelamer Carbonate is a polymeric amine that is not absorbed from the gastrointestinal tract. Its multiple amine groups become protonated in the intestine and bind dietary phosphate through ionic and hydrogen bonding, forming a complex that is excreted in the stool.
By reducing intestinal phosphate absorption, Sevelamer Carbonate lowers serum phosphorus concentrations without providing a systemic calcium load, unlike calcium-based binders. Modest reductions in LDL cholesterol have also been observed with sevelamer salts in some studies, though this is not an approved indication.
Dosage & Administration of Renosev
Adults on Dialysis
| Baseline Serum Phosphorus | Starting Dose of Renosev |
|---|---|
| 5.5-7.5 mg/dL (1.8-2.4 mmol/L) | 800 mg three times daily with meals |
| ≥7.5 mg/dL (≥2.4 mmol/L) | 1600 mg three times daily with meals |
The dose of Renosev is then titrated upward or downward by 800 mg per meal at intervals of about 2 weeks, based on serum phosphorus levels, until an acceptable phosphorus level is reached. Average maintenance doses of approximately 6-7 grams per day (in divided doses with meals) are commonly used.
Patients Switching from Sevelamer Hydrochloride
Renosev may be substituted for sevelamer hydrochloride on a gram-for-gram basis, with serum phosphorus monitored to confirm continued control.
Pediatric Patients (6 years and older, on dialysis)
| Body Surface Area (BSA) | Starting Dose of Renosev |
|---|---|
| 0.75-1.2 m² | 800 mg per meal |
| >1.2 m² | 1600 mg per meal |
Doses of Renosev are given three times daily with meals and titrated every 2 weeks initially, based on serum phosphorus response.
Administration Instructions
- Tablets of Renosev must be swallowed whole; do not crush, chew, or split, as this alters how the medicine works in the gut.
- Always take Renosev with meals (or immediately before/after eating); taking it without food substantially reduces its phosphate-binding effect.
- If a powder-for-suspension form of Renosev is prescribed, mix the full contents of the packet with the recommended amount of water and take immediately with a meal.
Administration of Renosev
Interaction of Renosev
Renosev can bind to certain oral medications in the gastrointestinal tract and reduce their absorption. Well-documented, clinically significant interactions include:
- Ciprofloxacin: Bioavailability reduced by approximately 50% when taken with Renosev; ciprofloxacin should be taken at least 2 hours before or 6 hours after Renosev.
- Mycophenolate mofetil: Peak concentration is reduced when co-administered with Renosev; mycophenolate mofetil should be taken at least 2 hours before Renosev, with levels monitored in transplant patients.
- Cyclosporine and tacrolimus (transplant patients): Reduced bioavailability has been reported with concurrent Renosev use; blood concentrations of these immunosuppressants should be monitored.
- Levothyroxine: Cases of hypothyroidism have been reported with concurrent use of Renosev; monitor TSH levels closely and consider separating dosing times.
- Other oral medications: For drugs with a narrow therapeutic index, it is prudent to administer the other medication at least 1 hour before or 3 hours after Renosev, unless separation has specifically been shown unnecessary.
No clinically significant interaction has been found between Renosev and digoxin, enalapril, iron, metoprolol, or warfarin at standard doses.
Contraindications
Sevelamer Carbonate is contraindicated in:
- Patients with known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or any component of the formulation.
- Patients with bowel obstruction.
Side Effects of Renosev
The most common side effects of Renosev seen in clinical trials are gastrointestinal and generally dose-related:
- Vomiting
- Nausea
- Diarrhea
- Dyspepsia (indigestion)
- Abdominal pain
- Flatulence
- Constipation
Less common but more serious gastrointestinal events have been reported with Renosev and other phosphate-binder resins, including dysphagia, tablet retention in the esophagus, bowel obstruction, bleeding, ulceration, perforation, and colitis; some cases required hospitalization or surgery. Seek prompt medical attention for severe abdominal pain, persistent vomiting, or inability to pass stool or gas while taking Renosev.
Hypersensitivity reactions such as rash and pruritus have been reported post-marketing with Renosev.
Pregnancy & Lactation
Pregnancy: Renosev is not absorbed systemically, so direct fetal drug exposure is not expected; however, data in pregnant women remain limited. Renosev should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk; a physician should be consulted before use. Because Renosev can reduce absorption of fat-soluble vitamins and folic acid, supplementation may be advised during pregnancy under physician guidance.
Lactation: As Renosev is not absorbed into the bloodstream, exposure of a breastfeeding infant through milk is not expected; however, use during breastfeeding should still be discussed with a physician, who can weigh individual circumstances and monitor for vitamin deficiency.
Precautions & Warnings
Renosev must always be taken with meals; taking it without food significantly reduces its phosphate-binding effect and therapeutic benefit.
- Swallowing difficulty: Use caution in patients with dysphagia or swallowing disorders, as tablet retention in the esophagus has been reported with Renosev; a powder-for-suspension formulation may be considered where available.
- GI motility disorders / major GI surgery: Use Renosev with caution in patients with significant gastrointestinal motility disorders, active inflammatory bowel disease, or a history of major gastrointestinal tract surgery, as the risk of bowel obstruction with binder resins may be increased (see Contraindications for outright bowel obstruction).
- Fat-soluble vitamin and folate deficiency: Long-term use of Renosev has been associated with reduced levels of vitamins A, D, E, K, and folic acid; periodic monitoring and supplementation may be considered per physician advice, especially with prolonged therapy.
- Drug absorption: See Interactions for medicines whose absorption can be reduced by Renosev and that require dose separation.
- Acid-base status: Because it does not deliver a bicarbonate load (unlike sevelamer hydrochloride), Renosev is generally preferred when acid-base status is a concern, but bicarbonate levels should still be periodically monitored in dialysis patients.
Overdose Effects of Renosev
Because Renosev is not absorbed from the gastrointestinal tract, the risk of systemic toxicity from overdose is low; doses up to 14 grams per day have been studied without a defined maximum tolerated dose. However, excessive doses could theoretically worsen gastrointestinal side effects or contribute to bowel obstruction, particularly in at-risk patients.
If an overdose of Renosev is suspected, or if the patient develops severe abdominal pain, persistent vomiting, or inability to pass stool or gas, seek immediate medical attention or contact a poison control center/emergency services. There is no specific antidote; treatment is supportive.
Storage Conditions
Store Renosev at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.
Use In Special Populations
Pediatric Use
Renosev is approved for use in pediatric patients 6 years of age and older with chronic kidney disease on dialysis, dosed according to body surface area (see Dosage & Administration). Safety and efficacy of Renosev in children under 6 years of age have not been established. Renosev may be less effective in children under 13 years of age with low baseline serum phosphorus.
Geriatric Use
Dose selection for elderly patients receiving Renosev should generally start at the lower end of the dosing range, reflecting the greater frequency of comorbidities and organ function decline in this age group.
Renal Impairment
Renosev is used specifically in patients with significant renal impairment (chronic kidney disease); because it is not systemically absorbed, no dosage adjustment based on residual renal function itself is required beyond phosphorus-guided titration.
Hepatic Impairment
No specific dosage adjustment of Renosev has been established for hepatic impairment; it has not been extensively studied in this population.
Duration Of Treatment
Reconstitution
For the powder-for-oral-suspension formulation of Renosev (available in some markets), empty the entire contents of one packet into a cup, add the recommended amount of water as specified on the product label, stir well, and drink the entire mixture immediately with a meal. Do not add the powder to hot liquids or heat the suspension, and do not store the reconstituted mixture for later use.
Drug Classes
Phosphate binder; non-calcium, non-absorbed polymeric amine.
Mode Of Action
Sevelamer Carbonate is a non-absorbed polymer containing multiple amine groups that become partially protonated in the intestine. These positively charged amine groups bind negatively charged phosphate ions from food via ionic and hydrogen bonding, forming a complex that is not absorbed and is eliminated in the stool. This reduces the amount of phosphate available for absorption into the blood, lowering serum phosphorus concentrations in patients with chronic kidney disease.
Pediatric Uses
Renosev is approved for the control of serum phosphorus in pediatric patients 6 years of age and older with chronic kidney disease on dialysis. Dosing is based on body surface area (see Dosage & Administration) and titrated according to serum phosphorus response. Renosev has not been shown to be effective in children under 13 years of age with baseline serum phosphorus below 5.6 mg/dL, and safety and efficacy in children under 6 years of age have not been established. Growth, nutritional status, and vitamin levels should be monitored during long-term use of Renosev in children.
Frequently Asked Questions
Q: Why do I need to take Renosev 800 mg Oral Powder with every meal?
A: Renosev 800 mg Oral Powder works by binding to phosphate from the food you eat while it is in your stomach and intestines. If you take it without food, there is little or no phosphate for it to bind, so it will not effectively lower your blood phosphorus level. Always take Renosev 800 mg Oral Powder with a meal or right before/after eating.
Q: Can I crush or chew the Renosev 800 mg Oral Powder tablets?
A: No. Tablets of Renosev 800 mg Oral Powder should be swallowed whole. Crushing, chewing, or splitting the tablet can change how it works in the gut and is not recommended unless your physician or pharmacist specifically advises otherwise.
Q: What should I do if I miss a dose of Renosev 800 mg Oral Powder?
A: Since Renosev 800 mg Oral Powder only works when taken with food, if you miss a dose simply skip it and take your next dose with your next meal as scheduled. Do not take a double dose to make up for the missed one.
Q: Can Renosev 800 mg Oral Powder be taken during pregnancy or breastfeeding?
A: Renosev 800 mg Oral Powder is not absorbed into the bloodstream, so direct exposure of the baby is not expected, but safety data in pregnant and breastfeeding women are limited. Renosev 800 mg Oral Powder should be used in pregnancy only if clearly needed, when the benefit outweighs the potential risk, and only under a physician's guidance; the same caution applies during breastfeeding. Because Renosev 800 mg Oral Powder can lower absorption of fat-soluble vitamins and folic acid, your physician may recommend supplements.
Q: What are the most common side effects of Renosev 800 mg Oral Powder?
A: The most common side effects of Renosev 800 mg Oral Powder are gastrointestinal: nausea, vomiting, diarrhea, indigestion, abdominal pain, gas, and constipation. These are usually dose-related. Rarely, more serious problems such as difficulty swallowing, tablets getting stuck in the esophagus, or bowel obstruction have been reported; seek prompt medical care for severe abdominal pain, persistent vomiting, or inability to pass stool or gas.
Q: Can I take my other medicines at the same time as Renosev 800 mg Oral Powder?
A: Renosev 800 mg Oral Powder can bind to certain oral medicines in the gut and reduce how much of them your body absorbs. For example, ciprofloxacin should be taken at least 2 hours before or 6 hours after Renosev 800 mg Oral Powder, and mycophenolate mofetil at least 2 hours before it. For other important medicines, it is generally safest to take them 1 hour before or 3 hours after Renosev 800 mg Oral Powder unless your physician tells you separation is not needed. Always tell your physician or pharmacist about all medicines you take alongside Renosev 800 mg Oral Powder.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.
